LT2961426T - Centrinės nervų sistemos susirgimų gydymas, per nosį įvedant imunoglobuliną g - Google Patents

Centrinės nervų sistemos susirgimų gydymas, per nosį įvedant imunoglobuliną g

Info

Publication number
LT2961426T
LT2961426T LTEP14714815.9T LT14714815T LT2961426T LT 2961426 T LT2961426 T LT 2961426T LT 14714815 T LT14714815 T LT 14714815T LT 2961426 T LT2961426 T LT 2961426T
Authority
LT
Lithuania
Prior art keywords
immunoglobulin
treatment
nervous system
central nervous
intranasal administration
Prior art date
Application number
LTEP14714815.9T
Other languages
English (en)
Inventor
William Frey
Leah Ranae HANSON
Sharon Pokropinski
Francisco RAUSA
Original Assignee
Baxalta GmbH
Baxalta Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta GmbH, Baxalta Incorporated filed Critical Baxalta GmbH
Publication of LT2961426T publication Critical patent/LT2961426T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
LTEP14714815.9T 2013-02-26 2014-02-25 Centrinės nervų sistemos susirgimų gydymas, per nosį įvedant imunoglobuliną g LT2961426T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361769673P 2013-02-26 2013-02-26
US201361862814P 2013-08-06 2013-08-06
PCT/US2014/018426 WO2014134070A1 (en) 2013-02-26 2014-02-25 Treatment of central nervous system disorders by intranasal administration of immunoglobulin g

Publications (1)

Publication Number Publication Date
LT2961426T true LT2961426T (lt) 2019-12-27

Family

ID=50424697

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP14714815.9T LT2961426T (lt) 2013-02-26 2014-02-25 Centrinės nervų sistemos susirgimų gydymas, per nosį įvedant imunoglobuliną g

Country Status (13)

Country Link
US (5) US9556260B2 (lt)
EP (2) EP2961426B1 (lt)
JP (1) JP6379113B2 (lt)
AU (2) AU2014223679B2 (lt)
DK (1) DK2961426T3 (lt)
ES (1) ES2759226T3 (lt)
HR (1) HRP20192111T1 (lt)
HU (1) HUE046752T2 (lt)
LT (1) LT2961426T (lt)
PL (1) PL2961426T3 (lt)
PT (1) PT2961426T (lt)
SI (1) SI2961426T1 (lt)
WO (1) WO2014134070A1 (lt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150100042A1 (en) * 2013-10-07 2015-04-09 Impel Neuropharma Inc. Muroid Family Nasal Device
US20170027963A1 (en) * 2014-04-10 2017-02-02 Patrick Crowley Delivery of non-steroidal agents to the brain via the nasal tract to treat neurological disorders
US11844859B2 (en) 2017-08-20 2023-12-19 Nasus Pharma Ltd. Dry powder compositions for intranasal delivery
CA3071552A1 (en) 2017-08-20 2019-02-28 Formulex Pharma Innovations Ltd. Dry powder compositions for intranasal delivery
WO2020163815A1 (en) * 2019-02-07 2020-08-13 Innomed Technologies, Inc. Ivig treatments for bell's palsy
US20230181027A1 (en) * 2019-06-28 2023-06-15 Mayo Foundation For Medical Education And Research Methods and materials for treating neuromyelitis optica spectrum diseases
WO2021030582A2 (en) * 2019-08-13 2021-02-18 Altimmune, Inc. Therapeutic agent effectiveness and its route of administration

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE348942B (lt) 1970-06-02 1972-09-18 Statens Bakteriologiska Labor
US5624898A (en) 1989-12-05 1997-04-29 Ramsey Foundation Method for administering neurologic agents to the brain
NZ298384A (en) 1995-01-23 1998-07-28 Direct Haler As Inhaler - single dose of particulate substance arranged in air flow passage
JP4543553B2 (ja) 1999-03-03 2010-09-15 オプティノーズ アズ 鼻用の送り込み装置
US6585957B1 (en) 2000-01-25 2003-07-01 Aeropharm Technology Incorporated Medicinal aerosol formulation
US20070254889A1 (en) 2001-04-23 2007-11-01 Lee-Way Jin Compounds and methods useful for rescuing cells from beta-amyloid toxicity and treatment of Alzheimer's disease
CA2462682A1 (en) 2001-10-04 2003-04-10 Protein Therapeutics, Inc. The use of gammaglobulin for the treatment of immune-mediated diseases
US20040101909A1 (en) 2002-08-20 2004-05-27 Hema-Quebec, 2535 Boul. Laurier, Ste-Foy, Quebec, Canada G1V 4M3 Purification of polyreactive autoantibodies and uses thereof
KR20070110087A (ko) 2005-02-23 2007-11-15 알자 코포레이션 중추신경계에 활성 약제의 비강 투여
US20090136505A1 (en) 2005-02-23 2009-05-28 Johanna Bentz Intranasal Administration of Active Agents to the Central Nervous System
WO2007074880A1 (ja) * 2005-12-28 2007-07-05 Chugai Seiyaku Kabushiki Kaisha 抗体含有安定化製剤
ES2409844T3 (es) * 2006-01-30 2013-06-28 Grifols Therapeutics Inc. Metodo para el tratamiento y la profilaxis de enfermedades relacionadas con la deposicion de amiloide utilizando IgM
WO2007095616A2 (en) 2006-02-15 2007-08-23 Ramot At Tel Aviv University Filamentous bacteriophage displaying protein as a binder of antibodies and immunocomplexes for delivery to the brain
WO2008154337A1 (en) 2007-06-08 2008-12-18 Healthpartners Research Foundation Pharmaceutical compositions and methods for enhancing targeting of therapeutic compounds to the central nervous system
CA2716521A1 (en) * 2008-02-29 2009-09-11 Baxter Healthcare S.A. Anti-amyloid .beta. activity of intravenous immunoglobulin (ivig) in vitro
US8622993B2 (en) 2009-12-18 2014-01-07 Healthpartners Research Foundation Device and method for delivering therapeutic substances to the maxillary sinus of a patient
AU2011212440B2 (en) 2010-02-04 2015-01-22 Csl Behring Ag Immunoglobulin preparation
US8772462B2 (en) * 2010-05-26 2014-07-08 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide

Also Published As

Publication number Publication date
HRP20192111T1 (hr) 2020-03-20
US20240117025A1 (en) 2024-04-11
PT2961426T (pt) 2019-12-09
JP2016512490A (ja) 2016-04-28
EP3597220A1 (en) 2020-01-22
EP2961426A1 (en) 2016-01-06
ES2759226T3 (es) 2020-05-08
JP6379113B2 (ja) 2018-08-22
AU2014223679A1 (en) 2015-09-24
US11851481B2 (en) 2023-12-26
AU2014223679B2 (en) 2018-11-29
US9556260B2 (en) 2017-01-31
DK2961426T3 (da) 2019-12-02
US20170044244A1 (en) 2017-02-16
US20140242067A1 (en) 2014-08-28
SI2961426T1 (sl) 2020-01-31
US20210101967A1 (en) 2021-04-08
PL2961426T3 (pl) 2020-02-28
EP2961426B1 (en) 2019-10-30
US20190055307A1 (en) 2019-02-21
US10144776B2 (en) 2018-12-04
AU2018260883B2 (en) 2020-08-06
WO2014134070A1 (en) 2014-09-04
HUE046752T2 (hu) 2020-03-30
AU2018260883A1 (en) 2018-11-29

Similar Documents

Publication Publication Date Title
IL285151B1 (en) Methods for the treatment of fgf21-related disorders
ZA201602839B (en) Methods of using interleukin-10 for treating diseases and disorders
PL2964315T3 (pl) Układ do leczenia dysfunkcji neuromotorycznej
EP2970317A4 (en) PYRIMIDODIAZEPINONE COMPOUNDS AND METHOD FOR THE TREATMENT OF DISEASES
EP2986306A4 (en) METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING
SI2961426T1 (sl) Zdravljanje motenj centralnega živčnega sistema z intranazalnim dajanjem imunoglobulina G
HK1226308A1 (zh) 使用白細胞介素-10治療疾病和病症的方法
EP3065818A4 (en) Treatment of central nervous system conditions using sensory stimulus
EP2976094A4 (en) METHOD FOR THE TREATMENT OF METABOLISM TROUBLES
GB201408387D0 (en) Treatment of respiratory disorders
HK1231386A1 (zh) 免疫疾病的治療
PT3192524T (pt) Preparação de hgf adequada para tratamento de distúrbios neurológicos
IL258593A (en) Compounds for the treatment of subculture disorders
EP2814474A4 (en) METHOD FOR THE TREATMENT AND PREVENTION OF DISEASES AND DISORDERS OF THE CENTRAL NERVOUS SYSTEM
GB2516138C (en) The treatment of inflammatory disorders
GB201607388D0 (en) Treatment of impulsivity-related disorders
IL263494A (en) Use of lithium benzoate to treat disorders of the central nervous system
HK1224220A1 (zh) 治療神經退化性失調的方法
TWI561235B (en) Increase of protein synthesis ameliorates synaptopathy-related neurological disorders
AU2020264350A1 (en) Treatment of central nervous system disorders by intranasal administration of immunoglobulin g
GB201522706D0 (en) Treatments of central nervous system conditions
EP2970118A4 (en) COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
GB201602784D0 (en) New treatment of CFTR-related disorders
SG10201802808SA (en) Method of treating ocular disorders
GB201413533D0 (en) Combination therapy for treating disorders of the vestibular system